Technical Analysis for CRDF - Cardiff Oncology, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Up | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Narrow Range Bar | Range Contraction | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| Down 3 Days in a Row | Weakness | 0.00% | |
| Down 4 Days in a Row | Weakness | 0.00% | |
| Oversold Stochastic | Weakness | 0.00% | |
| NR7 | Range Contraction | -3.32% | |
| Narrow Range Bar | Range Contraction | -3.32% | |
| Stochastic Reached Oversold | Weakness | -3.32% | |
| Inside Day | Range Contraction | -3.32% | |
| Wide Bands | Range Expansion | -3.32% |
| Alert | Time |
|---|---|
| Down 3% | about 17 hours ago |
| Fell Below Previous Day's Low | about 18 hours ago |
| Down 2 % | about 18 hours ago |
| Down 1% | about 18 hours ago |
| Up 2% | about 18 hours ago |
Get this analysis on your stocks daily!
- Earnings date: 05/02/2024
Cardiff Oncology, Inc. Description
Cardiff Oncology, Inc., a clinical-stage, oncology therapeutic company, develops drugs to treat various types of cancer, including leukemia, lymphomas, and solid tumors. Its lead drug candidate is onvansertib, a Polo-like Kinase 1 selective adenosine triphosphate competitive inhibitor that is in Phase Ib/II clinical trial in acute myeloid leukemia (AML); has completed a Phase I clinical trial in advanced solid tumors; and Phase Ib/II clinical trial for metastatic Colorectal Cancer in combination with FOLFIRI and Avastin. The company's onvansertib is also in Phase II clinical trial in combination with Zytiga for metastatic castration-resistant prostate cancer; Phase I clinical trial with various chemotherapies and targeted therapeutics, such as Beleodaq (belinostat); Quizartinib (AC220), a development stage FLT3 inhibitor; and Velcade (bortezomib) used in leukemias, lymphomas, and solid tumor cancers. It primarily serves pharmaceutical companies. Cardiff Oncology, Inc. has a research collaboration with Nektar Therapeutics for the treatment of metastatic colorectal cancer. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2020. Cardiff Oncology, Inc. was founded in 1999 and is headquartered in San Diego, California.
Classification
Sector: Healthcare
Industry: Diagnostics & Research
Keywords: Medicine Cancer Clinical Medicine Pharmaceutical Solid Tumors Drugs Cancer Treatment Oncology Phosphates Lymphoma Acute Myeloid Leukemia Chemotherapy Prostate Cancer Antineoplastic Drugs Colorectal Cancer Leukemia Targeted Therapy Advanced Solid Tumors Solid Tumor Cancers Adenosine Metastatic Colorectal Cancer Resistant Prostate Cancer Metastatic Castration Resistant Prostate Cancer Nektar Therapeutics
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 6.42 |
| 52 Week Low | 0.94 |
| Average Volume | 2,401,883 |
| 200-Day Moving Average | 2.27 |
| 50-Day Moving Average | 4.59 |
| 20-Day Moving Average | 4.31 |
| 10-Day Moving Average | 3.91 |
| Average True Range | 0.48 |
| RSI (14) | 31.97 |
| ADX | 27.23 |
| +DI | 12.21 |
| -DI | 26.81 |
| Chandelier Exit (Long, 3 ATRs) | 4.83 |
| Chandelier Exit (Short, 3 ATRs) | 4.55 |
| Upper Bollinger Bands | 5.61 |
| Lower Bollinger Band | 3.01 |
| Percent B (%b) | 0.07 |
| BandWidth | 60.31 |
| MACD Line | -0.35 |
| MACD Signal Line | -0.19 |
| MACD Histogram | -0.1537 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 3.54 | ||||
| Resistance 3 (R3) | 3.57 | 3.48 | 3.49 | ||
| Resistance 2 (R2) | 3.48 | 3.39 | 3.47 | 3.47 | |
| Resistance 1 (R1) | 3.34 | 3.34 | 3.29 | 3.31 | 3.45 |
| Pivot Point | 3.25 | 3.25 | 3.23 | 3.24 | 3.25 |
| Support 1 (S1) | 3.11 | 3.16 | 3.07 | 3.09 | 2.95 |
| Support 2 (S2) | 3.02 | 3.11 | 3.01 | 2.93 | |
| Support 3 (S3) | 2.88 | 3.02 | 2.91 | ||
| Support 4 (S4) | 2.86 |
